There is an error in affiliation 3 for author Darren P. Baker. Affiliation 3 should be: Sanofi Genzyme, Cambridge, Massachusetts, United States of America.
Survival curves for patients with EVD receiving supportive care only (n = 21) (solid line) or supportive care plus IFN β-1a treatment (n = 9) (dashed line). Survival was calculated from the date of consent for those receiving IFN β-1a treatment and date of admission for those in the control cohort, to the date of death. Survival plots were based on Kaplan-Meier estimates and the plots were compared using the log rank test (p = 0.026).
Citation: The PLOS ONE Staff (2017) Correction: Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. PLoS ONE 12(4): e0175930. https://doi.org/10.1371/journal.pone.0175930
Published: April 12, 2017
Copyright: © 2017 The PLOS ONE Staff. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.